NHC Stock Analysis: National HealthCare | NYSE MKT
Medical Care Facilities | NYSE MKT, USA | Market Cap: 3.565m USD | 12M Return: 93.9% | US6359061008 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.7M
EPS Trend: 80.5%
Rev. Trend: 98.2%
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
National HealthCare Corporation (NHC) is a vertically integrated senior care provider operating skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and behavioral health hospitals, reporting through two segments: Inpatient and Homecare and Hospice Services. Its service offerings span physician-directed medical care, physical/speech/respiratory/occupational therapy, memory care and sub-acute units for Alzheimers patients, personal care assistance, and behavioral health programs for adults and geriatric patients. Beyond direct care, NHC operates homecare and hospice agencies, pharmacies, and managed care insurance solutions, and also provides management, accounting, and financial services while leasing properties to third-party operators. The company was founded in 1971 and is headquartered in Murfreesboro, Tennessee.
As a Health Care Facilities operator, NHCs revenue is heavily tied to Medicare and Medicaid reimbursement rates, which are subject to periodic government adjustment, while the broader sector benefits from demographic tailwinds driven by the aging U.S. population. Its combined ownership of facilities, home health, hospice, pharmacy, and insurance arms is a relatively uncommon fully integrated model in the post-acute care industry.
- Skilled nursing occupancy and Medicare reimbursement rate updates
- Labor cost inflation pressures operating margins
- Aging population drives demand for senior care services
| Net Income: 140.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.11 > 1.0 |
| NWC/Revenue: 24.71% < 20% (prev 13.34%; Δ 11.38% < -1%) |
| CFO/TA 0.12 > 3% & CFO 188.8m > Net Income 140.3m |
| Net Debt (-183.7m) to EBITDA (233.6m): -0.79 < 3 |
| Current Ratio: 22.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.9m) vs 12m ago 1.70% < -2% |
| Gross Margin: 39.49% > 18% (prev 38.11%; Δ 1.37% > 0.5%) |
| Asset Turnover: 100.6% > 50% (prev 93.34%; Δ 7.27% > 0%) |
| Interest Coverage Ratio: 73.58 > 6 (EBIT TTM 187.9m / Interest Expense TTM 2.55m) |
| A: 0.25 (Total Current Assets 403.6m - Total Current Liabilities 18.3m) / Total Assets 1.54b |
| B: 0.58 (Retained Earnings 888.7m / Total Assets 1.54b) |
| C: 0.12 (EBIT TTM 187.9m / Avg Total Assets 1.55b) |
| D: 2.74 (Book Value of Equity 1.12b / Total Liabilities 408.9m) |
| Altman-Z'' = 7.23 = AAA |
| DSRI: 0.91 (Receivables 137.7m/142.1m, Revenue 1.56b/1.46b) |
| GMI: 0.97 (GM 38.11% / 39.49%) |
| AQI: 1.06 (AQ_t 0.24 / AQ_t-1 0.23) |
| SGI: 1.07 (Revenue 1.56b / 1.46b) |
| TATA: -0.03 (NI 140.3m - CFO 188.8m) / TA 1.54b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 227.11 with a total of 62,819 shares traded. Over the past week, the price has changed by -0.24%, over one month by +0.24%, over three months by +6.35% and over the past year by +93.88%.
Current recommended Stop Loss: 212.10 (which is 6.6% or 2.3 ATR below the current price).
National HealthCare has no consensus analysts rating.
| Analysts Target Price | 6.2 | -97.3% |
P/E Trailing = 25.128
P/E Forward = 9.8912
P/S = 2.287
P/B = 3.138
P/EG = 0.8241
Revenue TTM = 1.56b USD
EBIT TTM = 187.9m USD
EBITDA TTM = 233.6m USD
Long Term Debt = 32.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 18.3m USD (from shortTermDebt, last quarter)
Debt = 82.2m USD (corrected: LT Debt 32.5m + ST Debt 18.3m) + Leases 31.4m
Net Debt = -183.7m USD (calculated: Debt 82.2m - CCE 265.9m)
Enterprise Value = 3.38b USD (3.57b + Debt 82.2m - CCE 265.9m)
Interest Coverage Ratio = 73.58 (Ebit TTM 187.9m / Interest Expense TTM 2.55m)
EV/FCF = 23.08x (Enterprise Value 3.38b / FCF TTM 146.5m)
FCF Yield = 4.33% (FCF TTM 146.5m / Enterprise Value 3.38b)
FCF Margin = 9.40% (FCF TTM 146.5m / Revenue TTM 1.56b)
Net Margin = 9.00% (Net Income TTM 140.3m / Revenue TTM 1.56b)
Gross Margin = 39.49% ((Revenue TTM 1.56b - Cost of Revenue TTM 943.4m) / Revenue TTM)
Gross Margin QoQ = 40.71% (prev 38.43%)
Tobins Q-Ratio = 2.20 (Enterprise Value 3.38b / Total Assets 1.54b)
Interest Expense / Debt = 3.11% (Interest Expense 2.55m / Debt 82.2m)
Taxrate = 22.94% (42.5m / 185.4m)
NOPAT = 144.8m (EBIT 187.9m * (1 - 22.94%))
Current Ratio = 22.06 (Total Current Assets 403.6m / Total Current Liabilities 18.3m)
Debt / Equity = 0.07 (Debt 82.2m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = -0.79 (Net Debt -183.7m / EBITDA 233.6m)
Debt / FCF = -1.25 (Net Debt -183.7m / FCF TTM 146.5m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.05% (Net Income 140.3m / Total Assets 1.54b)
RoE = 12.94% (Net Income TTM 140.3m / Total Stockholder Equity 1.08b)
RoCE = 16.83% (EBIT 187.9m / Capital Employed (Equity 1.08b + L.T.Debt 32.5m))
RoIC = 9.93% (NOPAT 144.8m / Invested Capital 1.46b)
WACC = 7.27% (E(3.57b)/V(3.65b) * Re(7.38%) + D(82.2m)/V(3.65b) * Rd(3.11%) * (1-Tc(0.23)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.38 | Cagr: 1.02%
[DCF] Terminal Value 77.97% ; FCFF base≈128.1m ; Y1≈146.8m ; Y5≈216.1m
[DCF] Fair Price = 219.4 (EV 3.25b - Net Debt -183.7m = Equity 3.44b / Shares 15.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 30.16% | SUE: N/A | # QB: 0
Revenue Correlation: 98.20 | Revenue CAGR: 15.02% | SUE: N/A | # QB: 0